Phase 1 Study of the HS-10365 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this
study is to investigate the safety/tolerability and the pharmacokinetic profile of HS-10365
in Chinese advanced solid tumor patients. Anti-tumor activity will be also investigated in
this study.